Hudson Bay Capital Management’s Starling Oncology STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-15,200
Closed -$31.2K 1674
2025
Q2
$31.2K Hold
15,200
﹤0.01% 1282
2025
Q1
$17.3K Buy
+15,200
New +$11.8K ﹤0.01% 1231
2021
Q1
Sell
-242,676
Closed -$2.62M 946
2020
Q4
$2.62M Sell
242,676
-3,700
-2% -$38.1K 0.03% 334
2020
Q3
$2.55M Hold
246,376
0.04% 326
2020
Q2
$2.5M Buy
+246,376
New +$2.45M 0.04% 286

Other funds holding STLN

Hudson Bay Capital Management's STLN Position: Q3 2025 in Review

Hudson Bay Capital Management sold out of Starling Oncology (STLN) in Q3 2025, closing a stake of 15,200 shares — an estimated $31.2K sold.

Hudson Bay Capital Management first reported a position in STLN in Q2 2020 and held it in 5 quarters. The position peaked at $2.62M in Q4 2020. 108 funds tracked by Wall St. Rank hold STLN as of Q3 2025.

  • Hudson Bay Capital Management reported no remaining Starling Oncology position as of Q3 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 15,200 Starling Oncology shares in Q3 2025, an estimated $31.2K.
  • Hudson Bay Capital Management first reported a position in Starling Oncology in Q2 2020 and held it in 5 quarters.
  • Hudson Bay Capital Management's Starling Oncology position peaked at $2.62M in Q4 2020.
  • 108 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2025.

Based on Hudson Bay Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.